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Abstract
Morpholino oligonucleotides (MOs) are an effective, gene-specific antisense knockdown technology used in many
model systems. Here we describe the application of MOs in zebrafish (Danio rerio)f o rin vivo functional characteriza-
tion of gene activity.We summarize our screening experience beginning with gene target selection.We then discuss
screening parameter considerations and data and database management. Finally, we emphasize the importance of
off-target effect management and thorough downstream phenotypic validation.We discuss current morpholino lim-
itations, including reduced stability when stored in aqueous solution. Advances in MO technology now provide a
measure of spatiotemporal control over MO activity, presenting the opportunity for incorporating more finely
tuned analyses into MO-based screening. Therefore, with careful management, MOs remain a valuable tool for dis-
covery screening as well as individual gene knockdown analysis.
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MORPHOLINO-BASED SCREENING
IN ZEBRAFISH
Knockdown screens searching for novel genes and
pathways have been conducted using a variety of
technologies and model organisms. Early examples
include [1] in the nematode and [2] in fly tissue cul-
ture cells. Successful screening is synergistic, combin-
ing the respective advantages of a specific model
organism and technology to reveal unknown biol-
ogy. Nevertheless, each protocol has inherent biases
based on the selected screening parameters and
knockdown tool efficacy and specificity. Here we
summarize screening with zebrafish (Danio rerio)a sa
model organism using antisense morpholino oligo-
nucleotides (MOs) as the primary gene-specific
knockdown approach.
Zebrafish embryos are transparent and develop
externally, a combination of properties which
makes this an outstanding model organism for study-
ing early vertebrate development. Embryogenesis is
complete by 50 hours postfertilization (hpf) with the
development of nearly all major vertebrate organ
systems firmly established. MOs were our knock-
down tool of choice because of the ease of delivery
and their high efficacy throughout zebrafish embry-
onic and larval development (for a comprehensive
review of MO use and zebrafish embryo injection
technique see, [3, 4]). MOs are a synthetic derivative
of DNA with two major changes: (i) a six-membered
morpholine ring replaces the standard deoxyribose
ring, and (ii) a non-ionic phosphorodiamidate linkage
replaces the anionic phosphodiester bond [5]. The
resulting neutral charge and relatively small size (usu-
ally 25 bases in length) make diffusion the main driv-
ing force of spread throughout the embryo following
microinjection [6]. MOs are extremely effective
through 50 hpf but can lose efficacy in a sequence-
specific manner thereafter (see [4] for review).
Although we and others largely focused on this trad-
itional efficacy window, morpholino-based screening
has also been effective at identifying novel loci critical
for later developmental processes (e.g. [7]).
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well established for the zebrafish [8–10]. Although
these methods have generated numerous mutant
alleles, large-scale genetic analysis in vertebrates is
costly and both time- and labor-intensive including
the breeding, maintainance and analysis of many fish
over multiple generations. Classical chemical muta-
genesis screens efficiently generate altered genetic
loci but molecular characterization of the altered
loci remains relatively slow and arduous. Insertional
mutagens often permit accelerated locus identifica-
tion, but they still require housing and breeding of
many normal fish to generate the subset of mutant
animals for analysis. Therefore, a key advantage of
MO-based screening is the ability to generate
knockdown phenotypes in wild-type embryos, sig-
nificantly reducing infrastructural needs as compared
to a classical mutagenesis screening.
Furthermore, phenotypes obtained from random
mutagenesis approaches may be due to a gene whose
function has already been well characterized in pre-
vious work, resulting in potential redundancy of
efforts as our knowledge base of core vertebrate
genes grows. Because MOs must be designed
against specific sequences, an additional advantage
of MO-based screening is that it readily integrates
bioinformatics information into selecting target
genes of interest, thus minimizing redundancy
during the screening effort.
SCREENING DESIGN:
BIOINFORMATICSAND TARGET
GENE SELECTION CRITERIA
Target gene identification is the first step in MO
screening. We selected the secretome—a subset of
the genome encoding ligands, receptors and extra-
cellular molecules—because cellular context and
cell–cell signaling play extensive roles in vertebrate
biology and physiology [11, 12]. In particular, we
used bioinformatics tools to compare the transcrip-
tomes of the human, pufferfish (Fugu rubipes) and
zebrafish genomes to identify putative
co-translationally translocated (CTT) protein se-
quences [11, 13]. CTT secretome members have
hallmark amino-terminal signal sequences that can
be readily identified using secondary structure pre-
diction tools [14]. The combination of signal se-
quence prediction and comparative genomics
analysis establishes likely translational start sites for
members of the zebrafish secretome [13, 15]
(Figure 1A). Start site identification is a critical step
in MO design for large-scale morpholino-based gene
targeting because MOs are extremely effective as
translation inhibitors when targeted to the mRNA
start codon or upstream (non coding) se-
quences [3–6]. For detailed, comprehensive discus-
sions of the advantages and disadvantages of
translation-blocking versus splice-site targeting
MOs, see [3, 4].
SCREENING PROCESS: INJECTING
THE MOAND SELECTING
SCREENING DOSE
Standardization of the injection process, develop-
ment of a reproducible dose response curve, rapid
phenotyping, detailed data description and central
data collection were all critical elements for effective
morpholino-based screening. We will discuss each of
these topics in further detail.
Two elements are key to standardizing MO in-
jection: (i) the fishes’ genetic background, and (ii) the
MO dose. First, a parent population that reliably
provides large clutches of uniformly sized embryos
with little death or deformity greatly facilitates the
screening process. The object is to reduce the
amount of genetic background ‘noise’ so as not to
obscure the downstream phenotypic ‘signal’.
Second, standardizing MO dosing requires deter-
mining the dose range within which most MOs will
elicit a specific phenotype without overt non-specific
effects. We chose to define a 95% confidence interval
wherein most MOs would be >50% penetrant (i.e.
>50% of injected embryos showed a specific pheno-
type). To standardize the doses, we performed a pre-
screen calibration using 20 MOs targeting genes with
known embryonic loss-of-function phenotypes [16].
Nineteen of these initial 20 MOs yielded >50%
penetrance between 1.5 and 6ng. Indeed, most ap-
proached 90% penetrance within that dose range
(Figure 1B).
Using a dose curve rather than a single dose for
each MO also provides information regarding
phenotypic severity and MO toxicity. As MO
dosage increases, phenotypic penetrance improves,
which in turn increases phenotypic severity [6].
This remarkable effect allows us to examine particu-
lar components of a phenotype by adjusting MO
dosage. However, with increasing MO dosage
comes greater MO toxicity (as discussed below;
[17]). The dose curve also provides information on
182 Bedell et al.Figure 1: Workflow using morpholinos as a genetic screening tool. (A) The first step is to identify the target genes
to be screened.We identified our target sequences using bioinformatics tools and comparing human, zebrafish and
pufferfish genomes. Once the likely start site was identified, the MO was designed using standard MO-mRNA
target sequence binding parameters (reviewed in [4]). (B) Second, we established a standard dose curve. We de-
signed 20 MOs against genes with known phenotypes to establish a broad calibration curve for MO effectiveness.
(C) We standardized the subsequent screening process as much as possible. (I) For phenotype identification, we
used a team-based approach that catered to the individual scientists’ expertise. (II) We used specific biological
assays, for example microangiography, to improve the specificity of phenotypic description. (III) We standardized
written phenotypic descriptions as much as possible, using PATO-compliant terminology to enhance data communi-
cation. (IV) Finally, observed phenotypes were entered into the MODB database for organization, searchability
and data sharing. (D) For each phenotype observedwith aninitial MO, validation was essential to ensure the pheno-
type was gene-specific and not an off-target effect. (E and F) Once a phenotype was established as gene-specific,
that MO could be used to investigate new biology.
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injected embryos die) for each tested MO, a useful
upper limit number for subsequent testing using that
particular oligonucleotide synthesis. Together, this
core data set—penetrance and toxicity per dosage
amount, and LD50 per MO—improves our ability
to optimize phenotypic ‘signal’ versus off-target
‘noise’.
OFF-TARGET EFFECTS OF MOS
MO activities in zebrafish embryos include both
sequence-specific RNA binding as well as effects
not associated with loss of function of the targeted
locus [3, 6, 17–19]. The latter ‘off-target’ effects can
be a confounding variable when using MOs for the
assignment of function to sequence in zebrafish.
While the underlying mechanism of the off-target
effects is unknown, one well-described and relatively
consistent phenotype is p53-dependent neural tox-
icity [6, 17, 18] (Figure 2B, C and E, compared to
Figure 2A). This effect is dose-dependent and has
been estimated to be apparent in 15–20% of all
MOs when injected at standard efficacy doses
[3, 17]. This phenomenon was sufficiently consistent
to justify systematic co-injection with a morpholino
against p53 (p53 MO) to mitigate the neural toxicity
(Figure 2F). One important caveat is that
gene-specific, p53-dependent phenotypes will be
masked using this approach [17, 19]. This effect
serves as an important practical constraint on the
use of MOs when studying p53-dependent
processes.
A more extreme toxicity phenotype regularly
noted was severe overall deformity, or what many
in the zebrafish community have come to call the
‘monster’ phenotype (Figure 2D and E) [18, 20]. As
development progresses, ‘monster’ embryos show
one or more of the following: shortened and gnarled
tails, massive body curvatures and small heads and
eyes. In general, any consistently occurring pheno-
type observed in a screen should be carefully noted
and validated: such a result likely indicates non spe-
cific toxicity of the chosen technology (see
Validation section below).
SCREENING PROCESS:
PHENOTYPING ANALYSES
Morphological screening in zebrafish was pioneered
through chemical mutagenesis genetic screens [8, 9].
Important lessons learned from that seminal work
included the need for a process that balanced keen
observation with efficient throughput effected
through a team-based approach. The MO collection
was initially centralized, with aliquots distributed to
multiple laboratories for parallel screening work. To
harness the necessary expertise within this screening
approach, we organized several teams consisting of
multiple laboratory members as well as internal and
external collaborators, all of whom contributed a
wide variety of biological interests and expertise.
We distributed the work for identifying phenotypes
among multiple people, decreasing the effort burden
on any one person. This approach catered to the
expertise in specific organ system form and function
that each member of the team brought to the screen,
increasing the likelihood of identifying more subtle
phenotypes [Figure 1C (I)].
Gross morphological screening was based on clas-
sical forward genetic criteria [8, 9] and initially
focused on morphological landmarks readily visible
via a dissecting microscope. The resulting morpho-
logical screening pipeline was conducted on multiple
days during the weekly screening workflow, with
most screening conducted from 1 through 3 days
post fertilization (dpf) based on the high efficacy of
MOs during this developmental time-period [4, 6].
If a putative phenotype was noted in the first round
of injections, we flagged the respective MO for
re-injection confirmation, followed by validation
using a second morpholino of independent sequence
targeting the candidate RNA ([13]; see below).
We subsequently integrated more refined bio-
assays to focus screening efforts on individual
organs or targeted biological pathways. For example,
the Ekker and Verfaillie labs used several tools to
assess vascular and blood development and function.
Initially, injected embryos with largely normal gross
morphology were assessed using and histological
stain for blood cells on fixed embryos [21]. We
later replaced this time-consuming process with
functional assessment using a fli1:GFP; gata1:RFP
double transgenic line which permitted simultaneous
examination of vascular form and function under a
fluorescent microscope [13]. This line conveniently
doubled as an effective way to identify genes
required for hematopoietic development [22]
[Figure 1C (II)]. Parallel work in consortium labora-
tories was focused on identifying genes critical
for other biological questions, such as lipid metabol-
ism [13].
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REPORTINGTHE DATA
Accurate and accessible phenotypic description was a
critical component of screening success. Screening
team members’ instinctive response was to write de-
tailed descriptions using personalized vocabulary
based loosely on published literature and investigator
experience. The major drawback to such an
approach is that it facilitates neither long-term data
accessibility nor comparative standards within and
between screening members and screening teams.
Therefore, we established a systematic approach
with standardized phenotypic terminology based on
Phenotype and Trait Ontology (PATO)-compliant
nomenclature, an anatomically-based reference
ontology [National Center for Biomedical
Figure 2: Examples of off-target effects of MOs. (A) A normal wild-type embryo at 24 hpf.The brain is transpar-
ent (arrow) and the tail is not bent (arrowhead). The MO used for this demonstration is targeted against SP2054
with and without p53. SP2054 MO shows a nonspecific p53 activation that does not co-localize with the endogenous
expression pattern of the targetedgene [17]. (B^E) Examples of the standard toxicity seen in MO injected embryos
that are not co-injected with the p53 MO. These four images are placed in order of increasing severity. (B)T h i s
embryo demonstrates some neural death, seen as a black area in the brain where it should be transparent (arrow),
while the tail is somewhat bent (arrowhead). (C) This embryo shows more neural toxicity (arrows), and the tail is
significantly bent (arrowhead). (D) This embryo does not show significant neural toxicity (arrow). However, gnarled
tails are commonly noted due to MO toxicity (arrowhead). (E) This embryo shows a classic more severe,‘monster’
phenotype. This embryo has p53-induced neural toxicity (arrow), but it also shows a very shortened and gnarled
tail as well as small head and eyes. (F) Inhibition of p53 can attenuate common off-target effects. Shown is the
same SP2054 MO as was used above co-injected with the p53 MO at 3ng of each MO (therefore 6ng of
total MO). The brain is largely clear with little or no visible neural toxicity (arrow) while the tail remains fairly
normal (arrowhead).The monster phenotype can be found in p53 MO co-injected embryos but usually to a lesser
extent.
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.org/)]. We chose this method for several reasons.
First, standardized terminology improved informa-
tion sharing among the screening team(s) and collab-
orators, as well as with outside scientists, by making
phenotypic descriptions readily available to those
who did not examine the embryos directly.
Second, having defined terminology facilitated cen-
tral data collection into our Morpholino Database
(MODB; [15]) and permitted machine-based assess-
ment using both qualitative and quantitative queries.
For example, team members or collaborators could
search for specific phenotypes by sorting the database
according to a given PATO-compliant term to find
MOs with phenotypes associated with a specific
organ system [Figure 1C (III)].
MODB was initially created to store and organize
MOs and their corresponding observed phenotypes
that were recorded after observation from records in
their lab notebooks. However, we rapidly created a
second-generation database to allow real-time data
entry. This enabled screeners to record phenotypes
at the time of observation rather than transcribing
data later, reducing errors in the data transfer process
and decreasing the amount of time recording pheno-
types. The third-generation database made MODB
[15] a web-based tool, providing for simultaneous
data entry and making the results readily accessible
to any scientist looking for MOs associated with a
given phenotype. MODB remains online as a pub-
licly available community tool (http://morpholino
database.org) [Figure 1C (IV)].
AFTER SCREENING: PHENOTYPE
VALIDATION
Any MO-induced phenotype must be validated to
confirm that it is due to gene-specific effects. Several
standard protocols for validating a putative morphant
phenotype have been established (for detailed valid-
ation methods, see [3, 4]). First, a second MO of
independent (and typically non-overlapping) se-
quence can be designed against the target transcript.
A splice-site targeting MO [3] is now often used for
this purpose because it allows the phenotype to be
correlated with knockdown efficacy through quan-
titative measurements of altered or reduced transcript
levels via quantitative real-time PCR (qRT–PCR).
However, the second MO can also be a
translation-blocking MO with a different sequence
than the first. Regardless of the type of MO used for
validation, the purpose of this experiment is to de-
termine whether the resulting phenotypes overlap, as
would be expected for independent MOs targeted to
the same gene. For known genes with available anti-
bodies, it is possible to validate efficacy with western
blotting or related immunohistochemical methods to
correlate reduced protein levels of the targeted gene
with an observed phenotype (Figure 1D).
RNA rescue is another valuable validation
method: the MO of interest and mRNA of the tar-
geted gene (free of the MO targeting sequence) are
co-injected and embryos are examined for amelior-
ation of the gene-specific phenotype. For many
genes with localized expression, MO knockdown
followed by ubiquitous mRNA delivery seldom re-
sults in truly wild-type animals. Instead, the expect-
ation is for rescue of a specific pathway or biological
process within the more comprehensive in vivo
setting.
If a mutant is available in a gene of interest, the
morphant and mutant phenotypes should be com-
pared. Validation is thus addressed where the two
phenotypes agree. However, several issues may com-
plicate a direct correlation between mutant and mor-
phant. First, translation-blocking MOs can uncover
maternally provided gene activity [6] resulting in
phenotypes not noted in zygotic-only homozygous
mutant animals. For some loci, generating combined
maternal/zygotic mutations can circumvent this po-
tential concern. Second, many mutations may only
be hypomorphic in nature, with the resulting homo-
zygous animals retaining some gene function. One
way to address this latter concern is to conduct
low-dose MO injections into heterozygous mutant
embryos and compare those against injections into
wild-type sibling embryos. The mutant genetic
background should be permissive for the MO
phenotype of interest.
We also assessed the uniqueness of the observed
phenotype with respect to the overall collection. For
example, an observed phenotype with a signature
effect on specific aspects of biology when compared
to the collected results from the hundreds of other
MOs was used as corroborating evidence that the
phenotype in question is likely gene-specific
[13, 15]. For example, using this criterion in the
secretome screen, 26/150 putative gene targets
yielded likely gene-specific knockdowns [13],
whereas 16 of 64 targets tested in the more focused
hematopoietic screen yielded likely genes necessary
for blood development [22]. In contrast, when
186 Bedell et al.multiple MOs induce the same phenotype, the result
is potentially an off-target effect. This correlated
dataset operates as an ongoing internal control.
USING MOS TODAY:THOUGHTS
AND CAVEATS FROM OVER A
DECADE OF FIELD USE
In the past decade, one noteworthy issue that some-
times affects the practical use of this reagent has been
reagent storage in aqueous solution. In some cases,
activity will be reduced after only a few weeks.
A particularly problematic additional effect is that
MO solutions can have a marked tendency to de-
velop small precipitates that clog the needles used to
deliver MOs via microinjection. Signal to noise
effects can sometimes be altered in older aqueous
MO aliquots. For example, increased background
toxicity can be apparent with longer storage in aque-
ous solution. Whether these observations of an in-
verse relationship between MO activity and MO
toxicity as storage time persists are associated with
the same process is unknown. One working hypoth-
esis is the ‘increased purity’ model, in which more
homogeneous MO syntheses (from newer chemis-
tries) result in a higher likelihood of insolubility
issues. Indeed, the manufacturer has recommended
autoclaving MOs when this phenomenon has been
observed (J. Moulton, personal communication).
One method we currently use for addressing the
reduced shelf life has been to make separate
vacuum-dried aliquots of MO and to only generate
aqueous working solutions immediately before con-
ducting microinjection experiments for phenotypic
assessment. Additional efforts are ongoing in the field
to address the insolubility problems.
The preferred approach in the field to distinguish
specific effects from off-targeting phenotypes is now
to use MOs that have available validation measure-
ments—such as splice-altering MOs with qRT–
PCR or translation-blocking MOs with antibodies.
These approaches confirm the efficacy of MO tar-
geting but do not directly address specificity. With
the ever-expanding options for either identifying or
generating mutants in desired genes using targeting
induced local lesions in genomes (TILLING) [23–25]
or custom-designed restriction endonucleases (ZFN)
[26, 27], the field is more regularly turning to a ref-
erence mutant phenotype as a validation approach.
Managing off-target effects has become an in-
creasingly important issue in dealing with MO
injections: to disregard off-target issues is to poten-
tially obscure data or to unintentionally classify un-
intended side-effects as genuine data. This is a
particularly sensitive issue because peer reviewers
from disparate fields may not have the necessary
expertise to distinguish MO-induced toxicity from
genuine, gene-specific MO-induced phenotypes.
Therefore, we now regard co-injection with
p53–MO as a crucial initial toxicity management
tool [17, 19].
MORPHOLINOS OF THE FUTURE
MOs continue to be a valuable tool for the field, and
advances to this technology are still being made. For
example, photocleavable caged MOs [22, 23] attach
a spatiotemporal control mechanism to standard MO
antisense functionality. Drawing its inspiration from
the rich background of inducible gene expression
technologies, this important development permits
the user to confine MO activity within a region of
the embryo at a chosen timepoint. Whereas
first-generation MO knockdown encompasses the
entire embryo, this new mechanism adds a level of
control that allows for experimentation at a cellular
level within an invivo setting.
CONCLUDING REMARKS
MO-based screening in zebrafish is an achievable
and highly informative undertaking, provided key
elements of experimental design are thoughtfully
handled and tested during the prescreening phase,
toxicity issues are carefully managed and responsive-
ness to unanticipated issues is built into the design. In
our experience, harmonizing the screening process
to a shared reference protocol lead to increased prod-
uctivity with a reduced time burden on any particu-
lar participant, maintaining peak observational skills
of the participating scientists. Furthermore, we rec-
ommend a team-based screening approach that in-
corporates the expertise of the scientists involved.
Specifically, we standardized three critical elements
of the screening process: (i) the MO dose curve to
optimize phenotype recognition, (ii) the termin-
ology used to report phenotypes to streamline data
communication and (iii) the reporting format to en-
hance data accessibility for electronic searches using
both quantitative and qualitative queries. Finally, we
cannot emphasize strongly enough the necessity of
careful validation of gene-specificity for each
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the novel biology revealed by the next generation of
morpholino-based screening.
Key Points
  MOs can be used to functionally annotate unknown genes in
zebrafish.
  Effective screening requires the use of standardized screening
protocols.
  Managementofoff-targeteffects such asneural toxicityis a crit-
ical bottleneck for discerning signal from noise for phenotypic
assessment.
  Validation ofpotentialgene-specific effectsis essential.
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